Intra-Cellular Therapies Inc.
ITCI
ITCI was delisted on the 1st of April, 2025.
274 hedge funds and large institutions have $3.85B invested in Intra-Cellular Therapies Inc. in 2022 Q3 according to their latest regulatory filings, with 43 funds opening new positions, 103 increasing their positions, 86 reducing their positions, and 35 closing their positions.
23% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 35
20% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 86
13% more call options, than puts
Call options by funds: $21.3M | Put options by funds: $18.9M
3% more funds holding
Funds holding: 266 → 274 (+8)
16% less capital invested
Capital invested by funds: $4.57B → $3.85B (-$727M)
36% less funds holding in top 10
Funds holding in top 10: 11 → 7 (-4)
Top Buyers
| 1 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$46.1M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$45.3M |
| 3 |
Millennium Management
New York
|
+$42M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$36.3M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$34.3M |
Top Sellers
ITCI Hedge Fund Activity: Q3 2022 in Review
274 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2022, worth a combined $3.85B — down 16% from $4.57B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new ITCI positions and 35 closed out — a net gain of 8 holders — while 103 added to existing stakes and 86 trimmed.
The largest buyer was GW&K Investment Management, adding an estimated $46.1M. The largest seller was Victory Capital Management, cutting an estimated $43.9M.
- 274 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2022, up from 266 in Q2 2022.
- Funds reported $3.85B of Intra-Cellular Therapies Inc. stock for Q3 2022, down 16% quarter-over-quarter.
- 43 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2022 and 35 closed out, a net change of +8 holders.
- The largest Intra-Cellular Therapies Inc. buyer in Q3 2022 was GW&K Investment Management, an estimated $46.1M added.
- The largest Intra-Cellular Therapies Inc. seller in Q3 2022 was Victory Capital Management, an estimated $43.9M sold.
Based on aggregated 13F filings for Q3 2022.